 NEW YORK, Sept. 23, 2021 GLOBE NEWSWIRE -- SELLAS Life Sciences Group, Inc. NASDAQ: SLS SELLAS or the Company, a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that on September 10, 2021 the United States District Court for the District of New Jersey the Court issued an order the Preliminary Order providing for preliminary approval of the proposed settlement of the claims relating to the Companys predecessor, Galena Biopharma, Inc., and asserted derivatively on behalf of the Company against the individual defendants named in the previously disclosed stockholder derivative actions i Keller v. Ashton, et al, Civil Action No. 2:17-cv-1777 D.N.J.; and ii Johnson v. Schwartz, et al, Civil Action No. 2:18-cv-00903 D.N.J. pending before the Court in accordance with the Stipulation of Settlement, dated June 15, 2021 the Stipulation. The Stipulation also resolves all claims asserted in another derivative action arising from the same facts, Jacobs v. Schwartz, et al, Case No. CIVMSC17-01222, Calif. Sup. Ct., Contra Costa. The Stipulation calls for the Company to adopt certain policies relating to the potential future commercialization of the Companys clinical candidates and for the Companys insurer to pay plaintiffs counsel up to 270,000 in attorneys fees and reimbursement of expenses. The Preliminary Order set a final settlement approval hearing for November 19, 2021. 